The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

This content is distributed under a Creative Commons CC BY-SA 4.0 license. You may freely reproduce the text, videos and images it contains, provided that you indicate the author’s name and ...